Skip to main content
  • AACR Publications
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

  • Register
  • Log in
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Focus on Computer Resources
    • 75th Anniversary
    • Meeting Abstracts
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • OnlineFirst
    • Editors' Picks
    • Citations
    • Author/Keyword
  • News
    • Cancer Discovery News
  • AACR Publications
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in

Search

  • Advanced search
Cancer Research
Cancer Research

Advanced Search

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Focus on Computer Resources
    • 75th Anniversary
    • Meeting Abstracts
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • OnlineFirst
    • Editors' Picks
    • Citations
    • Author/Keyword
  • News
    • Cancer Discovery News
Cellular and Molecular Biology 34: Apoptosis Regulators 2

Celecoxib (Celebrex®) induces apoptosis in MCF-7, BT-20, (breast carcinomas) A-375 (melanoma) and HT-29 (colorectal carcinoma) but does not activate Caspases 3, 8, or 9 in cells grown in monolayer

David H. Kinder, Ryan Schneider and Amy Aulthouse
David H. Kinder
Ohio Northern University, Ada, OH
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ryan Schneider
Ohio Northern University, Ada, OH
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Amy Aulthouse
Ohio Northern University, Ada, OH
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI:  Published May 2005
  • Article
  • Info & Metrics
Loading
Proc Amer Assoc Cancer Res, Volume 46, 2005

Abstract

2687

Celecoxib (Celebrex®, Pfizer) is a COX-2 selective anti-inflammatory agent used to treat arthritis and other inflammatory processes. It has recently been shown that Celecoxib will decrease the numbers of polyps in patients with Familial Adenomatous Polyposis (FAP) for which it now has FDA approval. Evidence is mounting that Celecoxib will decrease the incidence of breast cancer, and may have usefulness in the treatment of several different tumor types as a chemotherapeutic agent. Several studies have been conducted examining activation of caspase 3 in response to Celecoxib, with no clear results. Thus, we undertook the study of Celecoxib and its affects on 4 tumor cell lines in monolayer, as well as in an agarose suspension method we recently developed. We found that Celecoxib inhibits growth of the BT-20 and MCF-7 breast tumor cell lines as well as A375 melanoma and HT-29 colon carcinoma in monolayer. IC50 values of 60, 55, 45 and 50 μM, respectively, were obtained. We examined caspase expression, and found that Caspases 3, 8, and 9 were not activated in response to treatment at any time point. Staining with Hoechst Stain showed nuclear coalescence, but no DNA fragmentation was found to occur. In the agarose culture methods, where cells grow unattached to plastic, we did not observe cell death but did observe inhibition of mitosis as the treated cells did not form colonies when compared to control. Single cells were seen to be viable as indicated by lack of Trypan blue staining. This suggests that cell death caused by Celecoxib in monolayer does not involve the caspase pathways despite apoptotic appearance, but involves a different pathway altogether and may be unique to the monolayer growth.

  • American Association for Cancer Research
Previous
Back to top
Cancer Research: 65 (9 Supplement)
May 2005
Volume 65, Issue 9 Supplement
  • Table of Contents
  • Index by Author

Sign up for alerts

Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Cancer Research article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Celecoxib (Celebrex®) induces apoptosis in MCF-7, BT-20, (breast carcinomas) A-375 (melanoma) and HT-29 (colorectal carcinoma) but does not activate Caspases 3, 8, or 9 in cells grown in monolayer
(Your Name) has forwarded a page to you from Cancer Research
(Your Name) thought you would be interested in this article in Cancer Research.
Citation Tools
Celecoxib (Celebrex®) induces apoptosis in MCF-7, BT-20, (breast carcinomas) A-375 (melanoma) and HT-29 (colorectal carcinoma) but does not activate Caspases 3, 8, or 9 in cells grown in monolayer
David H. Kinder, Ryan Schneider and Amy Aulthouse
Cancer Res May 1 2005 (65) (9 Supplement) 632-633;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Celecoxib (Celebrex®) induces apoptosis in MCF-7, BT-20, (breast carcinomas) A-375 (melanoma) and HT-29 (colorectal carcinoma) but does not activate Caspases 3, 8, or 9 in cells grown in monolayer
David H. Kinder, Ryan Schneider and Amy Aulthouse
Cancer Res May 1 2005 (65) (9 Supplement) 632-633;
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Info & Metrics
Advertisement

Related Articles

Cited By...

More in this TOC Section

  • Molecular mechanisms of gossypol-mediated regulation of apoptosis in human prostate cancer cells
  • Identification of the molecular target for tumor selective apoptosis-inducing 3,5-diaryl-oxadiazole compounds
  • Modulation of p53 transcriptional activity: Effects on staurosporine-induced apoptosis of wild type and mutated p53 epithelial cells
Show more Cellular and Molecular Biology 34: Apoptosis Regulators 2
  • Home
  • Alerts
  • Feedback
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Meeting Abstracts

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians
  • Reviewers

About Cancer Research

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2018 by the American Association for Cancer Research.

Cancer Research Online ISSN: 1538-7445
Cancer Research Print ISSN: 0008-5472
Journal of Cancer Research ISSN: 0099-7013
American Journal of Cancer ISSN: 0099-7374

Advertisement